Claims for Patent: 9,155,699

Summary for Patent: 9,155,699

Title:	Pulmonary delivery for levodopa
Abstract:	In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.
Inventor(s):	Jackson; Blair C. (South Grafton, MA), Bennett; David J. (Brighton, MA), Bartus; Raymond T. (San Diego, CA), Emerich; Dwaine F. (Glocester, RI)
Assignee:	Civitas Therapeutics, Inc. (Chelsea, MA)
Application Number:	14/055,959
Patent Claims:	1. A composition of dry powder particles formulated for pulmonary delivery comprising about 75 weight percent levodopa or more and sodium chloride. 2. The composition of claim 1, wherein the particles further comprise a phospholipid or a combination of phospholipids. 3. The composition of claim 1, wherein the particles have a tap density about 0.4 g/cm.sup.3 or less. 4. The composition of claim 1, wherein the particles have a volume median geometric diameter about 5 micrometers or more. 5. The composition of claim 1, wherein the particles have an aerodynamic diameter of from about 1 micrometer to about 5 micrometers. 6. The composition of claim 1, wherein the particles have an aerodynamic diameter of from about 1 micrometer to about 3 micrometers. 7. The composition of claim 1, wherein the particles have an aerodynamic diameter of from about 3 micrometer to about 5 micrometers. 8. The composition of claim 1, wherein the particles have a tap density about 0.3 g/cm.sup.3 or less. 9. The composition of claim 1, wherein the particles have a tap density about 0.2 g/cm.sup.3 or less. 10. The composition of claim 1, wherein the particles have a tap density about 0.1 g/cm.sup.3 or less. 11. The composition of claim 1, wherein the particles comprise about 10% or less by weight of sodium chloride. 12. The composition of claim 1, wherein the particles comprise about 5% or less by weight of sodium chloride. 13. The composition of claim 1, wherein the particles comprise about 2% or less by weight of sodium chloride. 14. The composition of claim 2, wherein the phospholipid is dipalmitoyl phosphatidylcholine (DPPC). 15. A composition of dry powder particles consisting of about 75% or more levodopa, sodium chloride and dipalmitoylphosphatidylcholine. 16. A composition of dry powder particles consisting of levodopa, sodium chloride and dipalmitoylphosphatidylcholine, wherein the ratio of levodopa:dipalmitoylphosphatidylcholine:sodium chloride is about 90:8:2.